Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply
Cleveland, Ohio 44012, United States
Barranquilla, Atlántico 80020, Colombia
Maulbronn, 75433, Germany
Mexico City, Mexico City 04530, Mexico
Culiacan de Rosales, Sinaloa 80230, Mexico
Krasnodar, 350007, Russia
Nizhny Novgorod, 603155, Russia
Yekaterinburg, 620030, Russia
Pantelej-Nis, 18000, Serbia
Cheonan-si, Chungcheongnam-do 31151, South Korea
Torremolinos, Malaga 29620, Spain
Kyiv, 04080, Ukraine
Poltava, 36013, Ukraine
Ternopil, 46000, Ukraine
Glasgow, G51 4TF, United Kingdom